Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02862613Phase 1Unknown

Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer

Role: lead

NCT02862587Phase 1Unknown

Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer

Role: lead

NCT02862561Phase 1Unknown

Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer

Role: lead

NCT02862028Phase 1Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Role: lead

All 4 trials loaded